Document Detail

Conjunctival hemorrhagic events associated with imatinib mesylate.
MedLine Citation:
PMID:  18192104     Owner:  NLM     Status:  MEDLINE    
Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.
Franca Radaelli; Claudia Vener; Francesco Ripamonti; Alessandra Iurlo; Mariangela Colombi; Andrea Artoni; Gianluigi Reda; Giorgio Lambertenghi Deliliers
Related Documents :
17171094 - Huge meningiomas: a review of 93 cases.
22139774 - Effect of selected "desirable difficulty" learning strategies on the retention of physi...
24160964 - Effectiveness of medial rectus advancement alone or in combination with resection or la...
20483024 - Effects of minimally invasive techniques for evacuation of hematoma in basal ganglia on...
17667034 - Acquired pulmonary vein stenosis after radiofrequency ablation treated by angioplasty a...
21706214 - Single-center clinical comparison of two reinforced ureteral access sheaths for retrogr...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International journal of hematology     Volume:  86     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-01-14     Completed Date:  2008-03-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  390-3     Citation Subset:  IM    
Ematologia II-Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Francesco Sforza 35, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects*
Conjunctival Diseases / chemically induced*,  pathology
Drug Hypersensitivity / pathology
Follow-Up Studies
Gastrointestinal Stromal Tumors / drug therapy,  pathology
Hemorrhage / chemically induced*,  pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications,  drug therapy,  pathology
Middle Aged
Piperazines / administration & dosage,  adverse effects*
Pyrimidines / administration & dosage,  adverse effects*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron ...
Next Document:  Primary adult-onset macrophage activation syndrome with multisystemic tissue phagocytosis.